Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183896 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL4190567 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2BACE1 | |
| SCHEMBL4197217 | 0.81 | ALDH1A1 (0.39) | BACE1BTN3A1MAPT | |
| SCHEMBL4185504 | 0.80 | CYP19A1 (0.32) | — | |
| SCHEMBL4185511 | 0.80 | CYP19A1 (0.32) | — | |
| SCHEMBL4196906 | 0.80 | CYP19A1 (0.32) | — | |
| SCHEMBL13094532 | 0.80 | KLK7 (0.36) | CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL16147725 | 0.80 | KLK7 (0.36) | CYP3A4HTTSMN1; SMN2MAPT | |
| SCHEMBL14503044 | 0.80 | PRSS1 (0.40) | — | |
| SCHEMBL6599500 | 0.79 | DUT (0.30) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | KLAR ULRICH | 2009-01-15 | — | — | US | disclosed |
| US-7407975-B2 | Epothilone derivatives, method for producing same and their pharmaceutical use | BAYER SCHERING PHARMA AG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-1847540-A1 | Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1005465-B1 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060040990-A1 | Epothilone derivatives, process for their production, and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-02-23 | — | — | US | disclosed |
| US-7001916-B1 | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals | SCHERING, AG (DE) | 2006-02-21 | — | — | US | disclosed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
| EP-1161430-A2 | EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF AS PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000047584-A2 | EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF AS PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040990-A1 | Epothilone derivatives, process for their production, and their pharmaceutical use | PTGIS, PTGES, PTGES2 | SMYD2 4494/4885CYP3A4 872/4885HTT 3392/4885 |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | SMYD2 3810/4885CYP3A4 989/4885HTT 2800/4885 |
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | TUBB4A, TUBA1B, TUBB | SMYD2 4182/4885CYP3A4 1341/4885HTT 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.